Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageMesoblast is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from our proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.
In the company’s own words · 20-F filed Aug 29, 2025 · SEC EDGAR
Mesoblast Limited (MESO) reported revenue of $51M in H1 2026 (quarter ended Dec 31, 2025), up 1415% from the same quarter a year earlier. That came with a gross margin of 85% and net loss of $40M. For the full year FY2025, revenue was $17M (+191% year on year) and net income −$102M.
Raw charts
7 series · TTMAs reported to the SEC, without any scoring.